BofA lowered the firm’s price target on Teladoc (TDOC) to $7.50 from $8 and keeps a Neutral rating on the shares. Heading into 2026, the firm maintains its positive view on the drug distributor group and updates its price targets to reflect peer group multiple changes.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TDOC:
- Teladoc call volume above normal and directionally bullish
- Balancing Emerging Strengths and Persistent Headwinds: Maintaining a Hold on Teladoc Amid Mixed Growth Signals and Limited Near-Term Upside
- Teladoc Board Member J. Eric Evans to Retire
- Teladoc Amends Incentive Plan to Increase Shares
- Private Markets: Musk’s SpaceX targets 2026 IPO at valuation of $1.5T